当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Dunash ben Labrat
The field of drug discovery is constantly seeking innovative approaches to overcome the challenges associated with developing new therapeutics. Artificial Intelligence (AI) has emerged as a transformative technology with the potential to revolutionize the drug discovery process. This abstract provides an overview of the resources, methods, and applications of AI in drug discovery. It highlights the role of AI in addressing the complexities and costs of drug development, while emphasizing its potential to accelerate the identification of novel therapeutic targets and optimize lead compounds. The abstract also discusses the use of AI in clinical trial optimization and drug repurposing, demonstrating its versatility in different stages of the drug discovery pipeline. Additionally, it explores the challenges and limitations of AI, such as ethical considerations and regulatory hurdles, and offers insights into future directions and implications. Overall, this abstract highlights the significant impact of AI in drug discovery and its potential to transform the pharmaceutical industry by improving efficiency, accuracy, and success rates in the development of new treatments.